Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
November 13, 2025
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, everyone, and thank you for joining us for our business update and third quarter 2025 earnings call. Joining me today are Dr. James Cassella, our Chief Development Officer, and Farrell Simon, our Chief Commercial Officer. I'll share a few comments regarding the business and our financial results, and following that, the team will be happy to address any questions you may have. For Trevi, the first half of this year marked a significant turning point, driven by positive data readouts from the CORAL trial, which studied chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and also from the RIVER trial, which focused on patients with refractory chronic cough, or RCC. We shared those findings at CHEST not long ago, and the enthusiasm we saw from top opinion leaders as well as community pulmonologists was truly encouraging. With such compelling results behind us, we closed roughly $115 million in financing during June, which extends our cash runway through 2028 and lets us carry out the upcoming clinical trials across every indication; that's a thrilling stage to reach on our path, and we've moved ahead without delay. I'd like to give you a quick rundown of what the team has accomplished across each of our chronic cough indications. To push our IPF cough program forward, we just wrapped up two significant phase I trials. During our call, we can share that the FDA asked us to run a drug-drug interaction trial. That trial examined possible PK interactions occurring when nalbuphine ER is given alongside pirfenidone or nintedanib. Those two agents are anti-fibrotics and represent the standard of care for individuals with IPF as well as other progressive fibrotic conditions. Data from that trial arrived recently. We are happy to report that across every drug combination studied, no clinically meaningful shifts in pharmacokinetics appeared. These findings will be published down the road. Even so, nothing we observed should affect dosing within our phase III program. Additionally, our TIDAL study has advanced nicely. That study evaluates respiratory function along with the safety profile of nalbuphine ER among IPF patients. Let me remind everyone that the FDA asked for this trial, which was designed to see whether IPF patients might show any warning signs of respiratory depression after they received nalbuphine ER. During the study, those IPF patients stayed in a clinic for 10 days, and as the dose was escalated, their oxygen, carbon dioxide levels, and breathing rate were checked over certain intervals. An outside safety review committee conducted a scheduled look at the data from a sentinel group of patients and determined that, so far, no safety signals had emerged in the trial. Because of that finding, the committee granted permission for the study to finish enrolling patients. Both the DDI study and the respiratory safety study will have their available data included in the end of phase II meeting package. Regarding that end of phase II meeting, our expectation is to request it during this year's fourth quarter. What we're aiming to cover with the FDA centers on securing agreement regarding the phase III program for chronic cough among IPF patients, obtaining their feedback on the phase III study design along with other protocol parameters, and reaching consensus on any remaining NDA-enabling work that still needs completion; at the same time, our clinical team has been getting ready to launch the phase III program during the first half of next year and is actively securing key vendors and pinpointing sites for these global studies. Preparation has also been underway for a trial involving other non-IPF interstitial lung diseases, or ILD. Non-IPF ILD patients who have lung fibrosis along with chronic cough will make up this population. Our estimate puts these patients at roughly 228,000, and 50%-60% of them suffer from uncontrolled cough. That expands the market opportunity for IPF chronic cough by more than twofold, and these patients largely receive care from the very same pulmonologists who treat IPF patients. This allows our clinical and commercial efforts to remain efficient and generates synergies; once we have aligned on the IPF pivotal program, our plan is to seek a meeting with the FDA to talk over our study design and protocol for this indication too. After receiving FDA input, we will be ready to launch this study. Finally, we've been making progress on the next trial for refractory chronic cough. We expect it to be a phase IIb, parallel-arm, dose-ranging study, and we plan to launch it in the first half of next year. We're also working on writing the protocol and finding sites for this study. As you can see, there's a lot of planning going on at Trevi, plus preparatory work to get aligned with regulatory authorities and start several trials in the first half of next year. Doing these trials properly takes time. Once we have alignment and can see study starts approaching, we'll provide updates on what comes next. Now I'd like to walk through a quick summary of how we performed financially this quarter. The full set of results for the three months that closed on September 30, 2025 is available in the press release we issued ahead of this call, and also in our 10-Q, which we filed with the SEC today once the market had closed. Our reported net loss for the third quarter of 2025 was $11.8 million, compared with a net loss of $13.2 million in the same period of 2024. R&D expenses came in at $10.1 million for the third quarter of 2025, a decline from $11.2 million in the comparable quarter last year. The main reason for that drop was a reduction in clinical trial activity, because those studies had been enrolling patients during the previous year and shared their results in the first half of this one. Working against that decline were increased costs associated with our phase I programs that wrapped up recently, as well as expenses for personnel and related items. In the third quarter of 2025, G&A costs reached $3.8 million, compared with $2.9 million during the same quarter a year earlier, largely because of bigger professional fees and growth in personnel and related expenses. Those higher professional fees were mostly the result of added costs from our continuing efforts to prepare for SOX 404(b) compliance. As of September 30, 2025, our cash and investments totaled about $195 million. This cash and investments position provides runway into 2028, assuming we finalize development for each of our indications. We anticipate funding two phase III trials of Haduvio for treating chronic cough in IPF patients, plus a long-term extension covering those trials. We also expect to fund our planned phase IIb/III trial in chronic cough among non-IPF ILD patients, our upcoming trial in RCC patients, and our ongoing phase 1 supportive studies. To wrap up, Trevi holds strong data across two serious chronic cough conditions and is getting ready to move into the next development stage for all three chronic cough indications. Chronic cough is a debilitating condition, and no FDA-approved therapies currently exist for it. On top of that, our balance sheet remains solid, and we hold enough cash to complete the upcoming phase of development work, which may move these treatments nearer to the patients who need them. We see ourselves as well placed to carry out our plan and to create substantial value for shareholders across the next two years or so. That concludes what I had prepared to say. Jim, Farrell, and I are ready to answer whatever you'd like to ask. I'll now return the line to the operator so we can begin Q&A.
Ryan Deschner
executiveHello, and I appreciate the question a lot. Regarding the non-IPF ILD study, have you gotten more specific about which inclusion and exclusion criteria you'd aim for — especially when it comes to how chronic cough gets defined in those trials? And right from the start, is there any ILD you'd leave out of an initial study in this area? Thank you.
James Cassella
executiveHey, Ryan, Jim here. Appreciate you asking. We've had a number of productive conversations with our KOLs regarding the non-IPF ILD trial. As you can probably picture, a great deal of overlap will exist when it comes to the underlying lung disease. We're going to spell that out in a particular manner. For chronic cough, my sense is we'll proceed using the standard criteria. Usually, we consider a minimum threshold of coughing — something like 10 coughs each hour. That will align very closely with what the rest of our program is examining. I'd say those elements are coming together quite well. The key thing to keep in mind with a study like this is that although many patients will have a range of other comorbid conditions, our true focus for entry criteria is how much cough they're experiencing and how much lung damage, lung fibrosis they have. Those will serve as the defining characteristics for inclusion. There will be additional matters to handle concerning their comorbid conditions.
Jennifer Good
executiveJim, anything we're carving out?
James Cassella
executiveRight now, we aren't excluding anything in particular. Those fundamental criteria are what we'll rely on. Naturally, that covers a wide range of conditions. Once we move nearer to that inclusion stage, or get nearer to spelling out that protocol with a bit more detail, we might exclude 1 or 2. Mostly, lung disease and how much cough someone has will be the basis for it.
Ryan Deschner
analystExcellent.
Jennifer Good
executiveThank you.
Ryan Deschner
analystMuch appreciated. Perhaps just briefly regarding the DDI study — for a trial such as this one, or for later trials beyond IPF, chronic cough, and RCC, would you expect that any further studies of that kind might be required?
James Cassella
executiveYes, that sounds good, Brian, thank you. What we had performed was a DDI study examining our compound alongside pirfenidone and nintedanib, which serve as the primary anti-fibrotics in this area. Additional DDI trials will need to be conducted by us, determined by how the drug is metabolized; our compound is broken down through CYP, mainly the 2C9 and 2C19 types. A DDI trial focused on what would likely be a 2C9 inhibitor is coming. These matters are ones we'll discuss with the FDA. It is anticipated that a couple more phase I trials, plus no fewer than one additional DDI study, will be required of us.
Ryan Deschner
analystThank you very much.
Annabel Samimy
analystHello, everyone. Thank you for allowing me to ask. I simply wanted to get some clarity regarding the respiratory study. You received interim data from the DSMV indicating no problems had arisen. Is it necessary to finish that trial prior to holding the end of phase II meeting with FDA? Are there additional obstacles that must be overcome for that particular meeting? On a different note, could you perhaps provide some of the feedback that has come in so far from the CHEST meeting, what pulmonologists are thinking about this, and how you are beginning to consider going after the market you are focused on? Thanks.
James Cassella
executiveAbsolutely. Hello, Annabel. Regarding TIDAL, we finished a sentinel group consisting of 4 participants, and the intention was for our data monitoring committee to examine those participants; everything proceeded without issue. No safety concerns were found. We moved forward. To address what you asked, the data we have available will be included when we send in the package. That study does not need to be finished prior to our submission for the end of phase II meeting. What we aim for is to possess the complete dataset by the time that meeting takes place.
Jennifer Good
executiveRight. I'll start by addressing the second question first, then Farrell can discuss the approach to targeting the market. Annabel, our data was shown at CHEST as well as ERS. Attendance was strong; at ERS we had a single poster. It was almost impossible to get close to that poster. Plenty of interest. What stood out was that many of our investigators wanted to see the complete dataset, and their patients keep asking them when the next trial will begin. I'd say there's broad recognition that cough is a significant issue, and while anti-fibrotics have been studied extensively, very little effort has gone into areas that affect patients on a daily basis; our sessions are drawing considerable attention. The data has drawn considerable attention too; one evening we also held a reception that drew strong attendance from U.S. investigators eager to join our study. Truly encouraging. Jim and I were both present. I stayed quite occupied throughout. Farrell, I think I'll hand it to you to speak about how, given the feedback, you may be considering targeting the market.
Farrell Simon
executiveYes. Annabel, I appreciate you asking that. Looking at the marketplace, it's clear we have to elevate awareness of how heavy this disease burden really is — that effort is underway, it carries on, and we'll roll it out next year. Beyond that, there's the matter of targeting — specifically, how we approach dividing this market into segments. That's something we'll kick off next year as well, purely to confirm our field force is sized correctly to reach the main prescribers in this therapeutic area. Those are a few of the pieces. On an ongoing basis, we keep conducting research with physicians and payers so we can grasp how our updated target product profile, which reflects the favorable poll findings, comes across to doctors and payers in this space.
Annabel Samimy
analystGreat. Thank you.
Jennifer Good
executiveThanks, Annabel.
Leland Gershell
analystOh, excellent. Thank you for the information, and I appreciate you fielding questions. Only a few — I came in somewhat behind, so I apologize in case these were already addressed. Jennifer, as you approach that end of phase II meeting, is there anything specific you're hoping to clarify or resolve? I also had a question regarding drug-drug interactions: does Trevi need to conduct any interaction studies among patients who might be taking other opioids at the same time? Thanks.
James Cassella
executiveHi, Leland. It's Jim. Regarding the end of phase II meeting, the questions we typically bring will concern the protocol design, the endpoints, how long the study runs — essentially the practical details of the phase III. A complete final draft protocol will be sent to them, so they'll be holding that protocol during the discussion. We'll steer toward the more significant questions about the design, the criteria for including and excluding patients, the statistical methods we plan to use — fairly fundamental matters that are genuinely critical to pin down during this meeting. Once we leave that meeting, we'll know with complete certainty what the phase III requires from us.
Jennifer Good
executiveSafety database size too is an important one, right?
James Cassella
executiveRegarding the size of the safety database: we're going to go over how much long-term data collection might be needed. Also, as we mentioned earlier, there's the DDI study — and we did note that additional phase I work could be required to finalize certain items for the NDA submission. Likely we'll conduct one more drug-drug interaction study, one that covers how our drug gets metabolized, which happens via CYP pathways, specifically 2C9 and 2C19. Regulators will want us to run a drug-drug interaction study involving medicines that inhibit that pathway, so we can figure out what happens to pharmacokinetics. There may be additional phase I studies too, which we expect to talk over with the FDA during the end of phase II meeting.
Jennifer Good
executiveOne more thing, Waylen — your question was really about other opioids, I believe. Those come with contraindications. We've kept them out of the picture since, as you're aware, what we're working with are mu antagonists. Should someone be taking other opioids, the result would be opioid withdrawal — which, clearly, is extremely beneficial when it comes to addiction as well as from a labeling standpoint. That's why we contraindicate it in our studies, and the label will reflect the same.
Leland Gershell
analystOkay, that's clear. Quite useful. Thanks a lot.
Jennifer Good
executiveSure. Appreciate it, Leland.
Judah Frommer
analystYes. Hey, everyone. Appreciate you answering our questions. Could you perhaps share your current views regarding the possibility of adding the non-IPF ILDs into the phase III trial for IPF? Do you expect to receive any clarity on this matter when phase II concludes, in your view? Or is it necessary to hold off until that later interaction occurs? How do you feel about starting with both indications under a single label as opposed to an SNDA? Also, on a much broader note, any perspectives on shifts in CDER leadership and what they might mean for the program? Thank you.
Jennifer Good
executiveRegarding strategy, I'll take that one. Either of us could handle it, honestly. Judah, I believe we settled on leading with our best possible presentation and holding that end of phase II meeting. Jim has amassed substantial, strong data. Our goal is for the FDA to get current with where we stand — every study we've conducted, every dataset we've produced. We'll hint during that session that the larger program spans RCC and, more crucially, non-IPF ILD, which in our view rests on shared biology. That point will be raised. This meeting gives you just 60 minutes, and we'd rather not lose focus arguing over non-IPF ILD in that room, since — as Jim said — what matters is leaving with unambiguous direction for our phase III effort. Our aim is to safeguard that and keep it intact. The moment we sense we're aligned with the agency, we'll be ready to file a protocol for non-IPF ILD and ask for a type C meeting. With any luck, that request proves simple, following right after the IPF end of phase II. That was a strategic consideration, since we might have entered sooner, yet believed in putting our best foot forward. Now, on the CDER leadership shift, I'll let Jim add whatever he can too. Clearly, a new individual was appointed this week — someone from oncology. Whether that truly touches the divisions we deal with, I can't say. To me it's astonishing: prompt feedback, punctual, straightforward correspondence. How the FDA keeps it all running, I have no idea. Credit to them. Whether those changes at the top matter while you're running a clinical trial, I can't tell. Surely, once they review your NDA, it will. So far, it hasn't appeared to influence our work. I'm not certain. Jim, anything from you?
James Cassella
executiveNope. Beyond that, I'd just say that the degree to which they've responded quickly has really caught me off guard — that's been near the top of my list. You know, it's, "For me to receive this level of responsiveness is really out of the ordinary." So I'm quite happy with that.
Jennifer Good
executiveYeah.
James Cassella
executiveGreat.
Jennifer Good
executiveThanks, Judah.
Serge Belanger
analystHey there, good afternoon. In prior discussions, I believe you brought up the possibility that Haduvio could qualify for orphan drug exclusivity when it comes to IPF cough. I'm just wondering whether your thinking has changed at all on this, and if pursuing an orphan drug designation is something you plan to do during the upcoming end of phase II meeting with FDA. Thanks.
Jennifer Good
executiveJim is laughing over there since he extracted a promise from me. For IPF, we will be seeking orphan drug status. I typically caution folks that I don't want them reading too much into this. Even though orphan drug status has been granted for IPF, what we're talking about here is cough in IPF, and cough affects a wide range of patients; let's see what their response is. An application will be filed by us. My feeling is that this is something we ought to have clarity on. Jim had me commit that we wouldn't pursue it before completing our end of phase II meeting. He doesn't want them getting pulled into other tangential questions. Right after end of phase II wraps up, we intend to submit for it and learn where they stand regarding cough in IPF.
Serge Belanger
analystGot it. Thank you.
Jennifer Good
executiveThank you, Serge.
Roanna Ruiz
analystThanks, and good afternoon, all. I have a few things to ask. To start with, with the IPF space changing and the positive results that recently came out of United Therapeutics' TETON study, I wanted to know how that might change the way Haduvio is used by doctors and where it lands in their prescribing approach and treatment algorithm.
Jennifer Good
executiveFarrell, do you want to handle that one, or should I?
Farrell Simon
executiveYes, absolutely. I appreciate you asking that, Rowana. Honestly, not a great deal shifts on our end. Consider chronic cough and how heavily these patients are affected by the disease — doctors view treatment as something they'd use either as a first option or a second option. It might come prior to starting an anti-fibrotic, or it might come afterward. As for the medications and the recent clearances reaching the market, what they do is continue to delay how the disease advances, and they aren't delivering any beneficial effect when it comes to cough. So there remains a substantial role for treating chronic cough, and for using it alongside those anti-fibrotics that are either already available or may soon be available.
Jennifer Good
executiveRight. Farrell, one more thing from me as well. There's been plenty of talk about how better therapies and treatments for patients likely lead to better diagnosis. Those patient groups are probably going to expand. I believe there's a bit more attention on this disease now. With any luck, cough moves to the forefront once we actually have a treatment available. Clearly, having options is a wonderful thing for patients. My sense is that, on the whole, it likely expands the market too.
Roanna Ruiz
analystGot it, that's clear. A brief additional question regarding the TIDAL study. Now that you're able to finish enrollment, what are you hoping the results show under a best-case situation? Do you have any views on how that could affect the end-of-phase-II conversation with the FDA?
James Cassella
executiveYes. Hello, Jim here. We're examining standard respiratory measures — PO2, CO2, and breathing rate. A trial of this kind drew the FDA's interest simply to confirm there are no obvious signs of respiratory depression; we're using a quite basic method focused on essential respiratory variables and monitoring them. For this trial, the perfect result — and so far the data has been excellent — would be finding nothing at all. Finding nothing would mean no shifts appear in any of those measures. Dosing happens at night, and we observe these IPF subjects during sleep, which is viewed as a cautious, maximally sensitive way to do this; that's what the study is designed for — to genuinely detect whether anything is present. Naturally, having clear results with no effect on the program is what we'd want most here.
Jennifer Good
executiveJim, one more thing I'd mention — clearly we've had this in, let me think, 200 people by now, IPF patients in the clinic, and not once have we observed any signal. My sense is this will simply move alongside the safety database they're reviewing too.
James Cassella
executiveWithout a doubt.
Roanna Ruiz
analystThat’s clear, thank you.
Jennifer Good
executiveThank you, Rowana.
William Wood
analystHello, and I appreciate you handling our questions right now. We have a few that mostly center on the phase III. From what I gather, it appears you basically have your phase III package assembled in the manner you prefer. Naturally, that needs to be talked over with the FDA and either cleared or at minimum mutually accepted. I was wondering whether you might describe, perhaps at a broad level, what you have in mind regarding doses and/or timing, the titration you intend to move ahead with. Perhaps you could also remind us whether you plan to permit patients to take background anti-fibrotics during the trial. Will you be examining improvement in biomarkers as part of the trial? And finally, in brief, will this take place at the identical sites where your earlier phase IIs ran, or will you be expanding to additional locations?
James Cassella
executiveAbsolutely. I believe I can recall each of those.
Jennifer Good
executiveWe've got those written down.
James Cassella
executiveI've got them recorded, so. William, thank you. This is Jim speaking. When it comes to doses, CORAL proved to be an excellent trial for us since we gained a great deal of knowledge from it, among other things that it served as our definitive dose-ranging study; regarding where the dose goes from here, we put in substantial effort during the summer; we took a close look at both the 54 mg and 108 mg dose groups. Since we titrate upward, we could establish for individual subjects and by examining dosing groups that the 108 mg dose truly provided no meaningful additional benefit beyond the 54 mg b.i.d. dose. Therefore, 54 mg b.i.d. is going to serve as our highest dose from now on. As for the 27 mg b.i.d. dose, that one is a titration dose. We established it as a minimum effective dose during the CORAL study. It won't be viewed as a treatment dose; instead, it will be viewed as a titration dose. Another thing the CORAL trial taught us is that whenever we carry out our titration, which is what we've done across every program we've run so far, we observe that the majority of adverse events typical for this compound — which are primarily GI and CNS in nature — most of those appear when dosing begins. What we intend to do is stretch out somewhat further the once-a-night dosing at the 27 mg level, move into 27 mgs b.i.d., and afterward reach our 54 mg b.i.d. treatment dose; we're going to lengthen that titration window somewhat in order to reduce some of the earlier side effects we observe with the compound. Just a quick note on what the adverse events associated with nalbuphine ER tend to look like: we generally see some GI and some CNS effects. These tend to be transient, and these tend to be things that do resolve over time. That's the reason we're going to lengthen that titration window. As for your question regarding permitting background anti-fibrotics, more than 80% of our subjects in the CORAL study were taking either nintedanib or pirfenidone. Yes, we're going to permit approved anti-fibrotics as background medication. When it comes to biomarkers, we have no plans to examine those in any — well, we aren't going to examine those. Regarding the sites, if you remember, with CORAL, we conducted that study ex-U.S. We're going to return to the more successful sites in that region; we're also going to bring in a large number of U.S. centers. What's great about the Pulmonary Fibrosis Foundation is that it has more than 80 excellent care centers, and we're speaking with them about running our trial; we're going to bring in U.S. centers in a major way, along with Canada and Europe.
William Wood
analystUnderstood; that helped a lot. Thanks for taking all my questions. Just one quick final thing — the end of phase II package: after you’ve actually filed it and talked it through, are you going to pass that along to us and/or investors, the public, or is that simply how it will be shared, I suppose?
Jennifer Good
executiveYeah. No, that’s a fair question, William. I believe normally you hold the meeting, and after that you wait 30 days for the minutes. Generally, you want to hold off until you can look at the minutes, so that whatever we believe we heard, we truly see written down once we receive it. Once we have that information, we will certainly provide an update to the street. I mean, we most likely won’t issue a separate press release. I think during one of our earnings calls or at some venue, we’ll use it to bring people up to date. Yeah, it’s important information, no doubt.
William Wood
analystUnderstood, that's useful. Thanks a lot, and I'll rejoin the line.
Jennifer Good
executiveAll right, thank you, William.
Kaveri Pohlman
analystHello, and good evening. I appreciate you taking my question. First off, I'd like to ask how closely the present study mirrors actual patients, taking into account factors such as the inclusion and exclusion requirements, other medical conditions, or the use of additional medications? When it comes to upcoming studies in both IPF and RCC, are you intending to widen the eligibility requirements so that a more varied group of people can take part, or will those requirements remain unchanged?
James Cassella
executiveYes, hello, this is Jim speaking; for the phase III, we intend to keep this patient group as wide as we can. Our goal is genuinely to avoid turning it into a purely clinical trial population—instead, we want it kept broad. We're collaborating with the KOLs so we can truly fine-tune our criteria for who gets in and who doesn't, making it undeniably closer to real-world conditions. Beyond the requirement of an IPF diagnosis, we'll impose fewer limitations, though participants will need certain other attributes indicating they're reasonably healthy enough to take part in the study. I can assure you it's going to be as wide-ranging as we can manage, as close to real life as we can get.
Jennifer Good
executiveIt's not too much different than our IIb, right?
James Cassella
executivePretty similar, honestly. Actually, we're tweaking a couple of items so that it extends beyond our IIb; essentially, we'll permit—unless a medication is going to get in the way of our capacity to gauge cough or is going to directly affect cough within the study, their con meds will be permitted as usual. I'm not sure whether there's any — was there something more you wanted? Those two points, I believe, I've addressed.
Jennifer Good
executiveNo.
James Cassella
executiveOkay.
Kaveri Pohlman
analystGot it. Yeah, that's useful. I'd also like to get clarity on the RCC phase IIb trial — is the plan to evaluate the identical dosing schedule that was used in the phase IIa, or do you intend to also try out QD possibilities, given that the drug appears quite safe?
James Cassella
executiveYeah. In that trial, we're actually probably going to drop the top 108 dose; we'll also be looking into QD dosing, once-a-day dosing, in that study.
Kaveri Pohlman
analystAlso twice-daily?
James Cassella
executivePlus the twice-a-day option. So we'll likely include a 27 once-a-day group too, since, if you remember the results, our 27 twice-a-day amount worked roughly as well as the two larger doses.
Kaveri Pohlman
analystOkay, perhaps just one final item. Regarding the respiratory safety trial — it caught me off guard that the FDA requested it once you'd presented data from 200 patients. I'd still like clarity on whether you'll be evaluating effects over the long term. Is it necessary to keep patients enrolled so that information can be gathered, or is that not something they've mandated?
James Cassella
executiveMy sense is the FDA wants a highly particular trial conducted. I've encountered this kind of scenario previously, where instead of simply gathering adverse events, they prefer a more targeted and controlled investigation. It's their call to request such a study, and from what I can tell, things are progressing well. Apologies — what was the other part of your question?
Jennifer Good
executiveOver the long haul. What I mean is, our long haul.
James Cassella
executiveWithin our phase III program, we're going to be gathering data over the long term. Drawing on what we've seen from the FDA previously in this area, the expectation is that they will want roughly 52 weeks of safety data.
Kaveri Pohlman
analystSorry. All right. Thank you.
Jennifer Good
executiveThanks, Kaveri.
Jennifer Good
executiveThanks so much. We’re glad you could be with us on today’s call. Since this marks the close of earnings season, you’re likely just as pleased as we are. Have a wonderful time during the holidays ahead, and if any follow-up questions come up, we’ll be around after this call or tomorrow. Thanks again.
Operator
operatorThat wraps up this conference. We appreciate your participation in today's presentation. You're free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.